This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire

Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG105 1 , a pre-clinical investigational novel compound with broad potential to treat brain health diseases, excluding the Republic of Korea, China, Hong Kong, Macau and Taiwan

Sovargen receives upfront payment and is eligible for future milestone-dependent payments and royalties

Agreement further expands Angelini Pharma’s strong portfolio and deep therapeutic expertise in brain health, following a series of strategic partnerships in the space, including in orphan and rare epi

See Full Page